Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications.
adjuvant therapy
biomarkers
melanoma
stage III
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
27 Apr 2021
27 Apr 2021
Historique:
received:
31
03
2021
revised:
23
04
2021
accepted:
26
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
8
6
2021
Statut:
epublish
Résumé
Melanoma is one of the most aggressive skin cancers. The 5-year survival rate of stage III melanoma patients ranges from 93% (IIIA) to 32% (IIID) with a high risk of recurrence after complete surgery. The introduction of target and immune therapies has dramatically improved the overall survival, but the identification of patients with a high risk of relapse who will benefit from adjuvant therapy and the determination of the best treatment choice remain crucial. Currently, patient prognosis is based on clinico-pathological features, highlighting the urgent need of predictive and prognostic markers to improve patient management. In recent years, many groups have focused their attention on identifying molecular biomarkers with prognostic and predictive potential. In this review, we examined the main candidate biomarkers reported in the literature.
Identifiants
pubmed: 33925387
pii: ijms22094561
doi: 10.3390/ijms22094561
pmc: PMC8123895
pii:
doi:
Substances chimiques
Biomarkers
0
Biomarkers, Pharmacological
0
Circulating Tumor DNA
0
MicroRNAs
0
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Pathology. 2019 Aug;51(5):487-493
pubmed: 31266597
Clin Cancer Res. 2010 Mar 1;16(5):1577-86
pubmed: 20179230
J Invest Dermatol. 2020 Nov;140(11):2260-2267
pubmed: 32275975
Exp Cell Res. 2004 Aug 15;298(2):317-28
pubmed: 15265682
Expert Opin Biol Ther. 2017 Apr;17(4):475-483
pubmed: 28274138
Melanoma Res. 2017 Oct;27(5):439-447
pubmed: 28486243
Clin Cancer Res. 2020 Apr 15;26(8):1886-1895
pubmed: 32015020
Eur J Cancer. 2014 Oct;50(15):2668-76
pubmed: 25070294
Clin Cancer Res. 2016 Jun 15;22(12):3016-24
pubmed: 26783288
Eur J Cancer. 2005 Jan;41(1):45-60
pubmed: 15617990
J Immunother. 2019 Sep;42(7):265-268
pubmed: 31145230
Br J Dermatol. 2015 Apr;172(4):885-915
pubmed: 25354495
Cancers (Basel). 2020 Apr 13;12(4):
pubmed: 32295074
J Eur Acad Dermatol Venereol. 2020 Mar;34(3):e126-e129
pubmed: 31710393
Int J Mol Sci. 2021 Apr 07;22(8):
pubmed: 33917181
J Transl Med. 2012 Sep 05;10:185
pubmed: 22950745
Eur J Cancer. 2005 Jan;41(1):28-44
pubmed: 15617989
Oncogene. 2011 Aug 11;30(32):3477-88
pubmed: 21577205
Nat Med. 2021 Feb;27(2):256-263
pubmed: 33558721
Ann Oncol. 2018 Feb 1;29(2):490-496
pubmed: 29112704
Mol Oncol. 2016 Mar;10(3):371-3
pubmed: 26875532
Br J Cancer. 2020 Mar;122(7):1059-1067
pubmed: 32037400
J Clin Oncol. 1996 Jan;14(1):7-17
pubmed: 8558223
J Transl Med. 2012 Jul 09;10:85
pubmed: 22554099
Clin Cancer Res. 2016 Aug 1;22(15):3915-23
pubmed: 26960397
J Clin Oncol. 2014 Feb 20;32(6):579-86
pubmed: 24449238
Surg Oncol. 2016 Sep;25(3):184-9
pubmed: 27566021
J Clin Invest. 2018 Dec 3;128(12):5505-5516
pubmed: 30260323
Arch Dermatol Res. 2021 Jan;313(1):63-64
pubmed: 32382813
Lancet Oncol. 2020 Mar;21(3):358-372
pubmed: 32007138
BMC Cancer. 2018 Feb 5;18(1):130
pubmed: 29402264
Lancet. 2018 Sep 15;392(10151):971-984
pubmed: 30238891
Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):E5005-13
pubmed: 27503895
J Immunother Cancer. 2019 Dec 5;7(1):343
pubmed: 31806053
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
J Invest Dermatol. 2013 Feb;133(2):509-17
pubmed: 22931913
Dermatology. 2016;232(3):259-64
pubmed: 27173969
J Cancer. 2018 Jun 5;9(13):2249-2265
pubmed: 30026820
Cancers (Basel). 2020 Nov 24;12(12):
pubmed: 33255267
J Clin Oncol. 2020 Nov 20;38(33):3925-3936
pubmed: 32946353
J Clin Oncol. 2005 Nov 1;23(31):8057-64
pubmed: 16258104
Clin Epigenetics. 2017 Apr 4;9:34
pubmed: 28396701
N Engl J Med. 2017 Nov 9;377(19):1813-1823
pubmed: 28891408
Lancet Oncol. 2020 Nov;21(11):1465-1477
pubmed: 32961119
J Invest Dermatol. 2012 Jun;132(6):1689-97
pubmed: 22402438
Dermatol Ther. 2020 Mar;33(2):e13270
pubmed: 32061008
Expert Rev Mol Diagn. 2018 Jan;18(1):7-17
pubmed: 29115895
Eur J Cancer. 2008 May;44(7):946-53
pubmed: 18396036
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
Sci Rep. 2020 Apr 20;10(1):6623
pubmed: 32313236
Clin Cancer Res. 2009 Mar 1;15(5):1801-7
pubmed: 19223509
J Biol Chem. 1998 Nov 27;273(48):31801-5
pubmed: 9822646
Crit Rev Oncol Hematol. 2021 Jan;157:103187
pubmed: 33276181
Br J Cancer. 2011 Nov 22;105(11):1726-32
pubmed: 22045183
Front Oncol. 2020 Aug 25;10:1524
pubmed: 32984000
Nat Cell Biol. 2017 Nov;19(11):1348-1357
pubmed: 28991221
Pigment Cell Melanoma Res. 2014 Nov;27(6):1106-16
pubmed: 24995518
J Transl Med. 2011 May 26;9:78
pubmed: 21615918
J Exp Med. 2019 May 6;216(5):1061-1070
pubmed: 30975894
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20429-34
pubmed: 19915147
J Am Acad Dermatol. 2015 May;72(5):780-5.e3
pubmed: 25748297
Br J Dermatol. 2018 Feb;178(2):357-362
pubmed: 28386936
Eur J Cancer. 2021 Mar;145:29-37
pubmed: 33418234
Ann Oncol. 2019 May 1;30(5):815-822
pubmed: 30860590
J Eur Acad Dermatol Venereol. 2021 Jan;35(1):e35-e38
pubmed: 32580236
PLoS One. 2012;7(1):e29336
pubmed: 22235286
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
J BUON. 2017 Sep-Oct;22(5):1296-1302
pubmed: 29135116
Expert Rev Anticancer Ther. 2018 Aug;18(8):775-784
pubmed: 29923435
Br J Cancer. 2013 Apr 30;108(8):1641-7
pubmed: 23519055
BMC Cancer. 2017 Aug 10;17(1):536
pubmed: 28797232
Clin Cancer Res. 2020 Aug 15;26(16):4414-4425
pubmed: 32253232
Ann Oncol. 2019 May 1;30(5):804-814
pubmed: 30838379
J Clin Oncol. 2012 Nov 1;30(31):3819-26
pubmed: 23008288
Sci Rep. 2020 Sep 25;10(1):15745
pubmed: 32978468
Cell. 2015 Sep 10;162(6):1242-56
pubmed: 26359984
Clin Cancer Res. 2008 Aug 15;14(16):5173-80
pubmed: 18698035
Ann Oncol. 2020 Jan;31(1):153-159
pubmed: 31912791
Eur J Cancer. 2016 Mar;55:111-21
pubmed: 26790144
Ann Surg Oncol. 2012 Dec;19(13):4314-21
pubmed: 22772867
Br J Dermatol. 2014 Jul;171(1):108-14
pubmed: 24602025
Cancer Lett. 2018 Jun 28;424:1-8
pubmed: 29548820
J Clin Oncol. 2014 Mar 20;32(9):935-41
pubmed: 24516022
Sci Rep. 2020 Oct 29;10(1):18682
pubmed: 33122747
Clin Chem. 2020 Jan 1;66(1):169-177
pubmed: 31672856